Literature DB >> 11809984

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

J Angrill1, C Agustí, R de Celis, A Rañó, J Gonzalez, T Solé, A Xaubet, R Rodriguez-Roisin, A Torres.   

Abstract

BACKGROUND: A study was undertaken to investigate the incidence, diagnostic yield of non-invasive and bronchoscopic techniques, and risk factors of airway colonisation in patients with bronchiectasis in a stable clinical situation.
METHODS: A 2 year prospective study of 77 patients with bronchiectasis in a stable clinical condition was performed in an 800 bed tertiary university hospital. The interventions used were pharyngeal swabs, sputum cultures and quantitative protected specimen brush (PSB) bacterial cultures (cut off point > or =10(2) cfu/ml) and bronchoalveolar lavage (BAL) (cut off point > or =10(3) cfu/ml).
RESULTS: The incidence of bronchial colonisation with potential pathogenic microorganisms (PPMs) was 64%. The most frequent PPMs isolated were Haemophilus influenzae (55%) and Pseudomonas spp (26%). Resistance to antibiotics was found in 30% of the isolated pathogens. When the sample was appropriate, the operative characteristics of the sputum cultures were similar to those obtained with the PSB taken as a gold standard. Risk factors associated with bronchial colonisation by PPMs in the multivariate analysis were: (1) diagnosis of bronchiectasis before the age of 14 years (odds ratio (OR)=3.92, 95% CI 1.29 to 11.95), (2) forced expiratory volume in 1 second (FEV1) <80% predicted (OR=3.91, 95% CI 1.30 to 11.78), and (3) presence of varicose or cystic bronchiectasis (OR=4.80, 95% CI 1.11 to 21.46).
CONCLUSIONS: Clinically stable patients with bronchiectasis have a high prevalence of bronchial colonisation by PPMs. Sputum culture is a good alternative to bronchoscopic procedures for evaluation of this colonisation. Early diagnosis of bronchiectasis, presence of varicose-cystic bronchiectasis, and FEV1 <80% predicted appear to be risk factors for bronchial colonisation with PPMs.

Entities:  

Mesh:

Year:  2002        PMID: 11809984      PMCID: PMC1746176          DOI: 10.1136/thorax.57.1.15

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

1.  An investigation into causative factors in patients with bronchiectasis.

Authors:  M C Pasteur; S M Helliwell; S J Houghton; S C Webb; J E Foweraker; R A Coulden; C D Flower; D Bilton; M T Keogan
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Bacteriology of lower-respiratory-tract secretions, sputum, and upper-respiratory-tract secretions in "normals" and chronic bronchitics.

Authors:  A W LEES; W MCNAUGHT
Journal:  Lancet       Date:  1959-12-19       Impact factor: 79.321

3.  Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.

Authors:  N Soler; S Ewig; A Torres; X Filella; J Gonzalez; A Zaubet
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

4.  Bacteriologic flora of the lower respiratory tract.

Authors:  G A LAURENZI; R T POTTER; E H KASS
Journal:  N Engl J Med       Date:  1961-12-28       Impact factor: 91.245

5.  Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis.

Authors:  A T Hill; E J Campbell; S L Hill; D L Bayley; R A Stockley
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

6.  Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis.

Authors:  P L Shah; S Mawdsley; K Nash; P Cullinan; P J Cole; R Wilson
Journal:  Eur Respir J       Date:  1999-12       Impact factor: 16.671

7.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.

Authors:  M Miravitlles; C Espinosa; E Fernández-Laso; J A Martos; J A Maldonado; M Gallego
Journal:  Chest       Date:  1999-07       Impact factor: 9.410

8.  Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study.

Authors:  H Cabello; A Torres; R Celis; M El-Ebiary; J Puig de la Bellacasa; A Xaubet; J González; C Agustí; N Soler
Journal:  Eur Respir J       Date:  1997-05       Impact factor: 16.671

9.  Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study.

Authors:  K A Miszkiel; A U Wells; M B Rubens; P J Cole; D M Hansell
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

10.  The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis.

Authors:  P L Ho; K N Chan; M S Ip; W K Lam; C S Ho; K Y Yuen; K W Tsang
Journal:  Chest       Date:  1998-12       Impact factor: 9.410

View more
  81 in total

Review 1.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Bronchiectasis exacerbations: The role of atypical bacteria, respiratory syncytial virus and pulmonary function tests.

Authors:  Eugenios I Metaxas; Evangelos Balis; Joseph Papaparaskevas; Nicholas Spanakis; Georgios Tatsis; Athanasios Tsakris
Journal:  Can Respir J       Date:  2015-04-15       Impact factor: 2.409

4.  β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.

Authors:  Elizabeth Story-Roller; Christos Galanis; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 5.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

Review 6.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Systemic humoral immunity to non-typeable Haemophilus influenzae.

Authors:  P T King; J Ngui; D Gunawardena; P W Holmes; M W Farmer; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 8.  Is bronchoscopy an obsolete tool in cystic fibrosis? The role of bronchoscopy in cystic fibrosis and its clinical use.

Authors:  Lisa Paul
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 9.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

10.  Cigarette Smoke Exposure Promotes Virulence of Pseudomonas aeruginosa and Induces Resistance to Neutrophil Killing.

Authors:  Jason Chien; John H Hwang; Sedtavut Nilaad; Jorge A Masso-Silva; Sae Jeong Ahn; Elisa K McEachern; Alexander Moshensky; Min-Kwang Byun; Laura E Crotty Alexander
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.